In the BioHarmony Drug Report Database
Cemiplimab-rwlc
Libtayo (cemiplimab) is an antibody pharmaceutical. Cemiplimab was first approved as Libtayo on 2018-09-28. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat squamous cell carcinoma. The pharmaceutical is active against programmed cell death protein 1.
Trade Name
|
Libtayo |
|---|---|
Common Name
|
cemiplimab |
ChEMBL ID
|
CHEMBL4297723 |
Indication
|
squamous cell carcinoma |
Drug Class
|
Monoclonal antibodies: immunomodulating |
Image (chem structure or protein)
